ClinicalTrials.gg
CompletedNCT01940497SCHEARLYUpdated Nov 3, 2020Results posted

A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

A Phase 3 interventional study of Doxorubicin and Docetaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 54 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-03.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
65th of 366
240 · median 61
Started
2013
with 25 others
Phase 3
60 of 374
3 open now
Registered
206th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 65th largest by enrollment of the 366 interventional ones that give a count, is one of 26 that started in 2013, is one of 60 in phase 3, and was the 206th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This non-randomized, multicenter, open-label study will assess the safety and efficacy of subcutaneously administered trastuzumab in participants with early and locally advanced HER2-positive breast cancer in two sequential cohorts. First 120 participants will be treated with subcutaneous (SC) trastuzumab 600 milligrams (mg) vial (Cohort A) and the subsequent 120 participants will be treated with SC trastuzumab prefilled single use injection device (SID) (Cohort B). Participants from each cohort will receive neoadjuvant or adjuvant chemotherapy consisting of doxorubicin every 3 weeks (q3w) (1 cycle) for 4 cycles followed by paclitaxel weekly or docetaxel every 3 weeks (q3w) in combination with SC trastuzumab (600 mg) q3w for 4 cycles and a further 14 cycles of SC trastuzumab (600 mg) q3w alone. All participants will be followed up for 24 months after the last participant has received the last dose of study treatment, or earlier in case of withdrawal from the study, loss to follow-up or death.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed non- primary invasive adenocarcinoma of the breast. Stage of disease: T1-4 (T describes size of tumour from 1 to 4), N0-3 (N describes nearby lymph nodes), M0 (M describes distant metastasis)
  • -positive disease immunohistochemistry (IHC) 3+ or in situ hybridization (ISH) positive
  • (ECOG) performance status 0-1
  • (LVEF) of greater than or equal to (>=) 55 percent (%) measured by echocardiography (ECHO) or multiple gated acquisition (MUGA) scan prior to first dose of trastuzumab SC
  • Intact skin at site of SC injection on the thigh

Exclusion criteria

Exclusion Criteria:

  • History of other , except for participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies, other than breast cancer, who have been disease-free for at least 5 years
  • Severe dyspnea at rest or requiring supplementary oxygen therapy
  • Concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness
  • Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, valvular disease, evidence of transmural infarction on (ECG), diagnosed poorly controlled hypertension
  • Known infection with (HIV), active virus (HBV) or virus (HCV)
  • Pregnant or lactating women
  • Concurrent enrolment in another clinical trial using an anti-cancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment
  • Known to trastuzumab, murine proteins, to any of the of Herceptin including hyaluronidase, or the adhesive of the SC device (for Cohort B), or a history of severe allergic or immunological reactions, for example, difficulty to control asthma
  • Inadequate bone marrow, hepatic or renal function
  • Hormonal treatment concomitant with chemotherapy (allowed in adjuvant phase with adjuvant trastuzumab SC)
  • Pre-existing motor or sensory neuropathy of Grade greater than (>) 1
  • Synchronous bilateral invasive breast cancer
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Trastuzumab (Vial)

    Participants will receive trastuzumab 600 mg SC using a vial q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy \[consisting of doxorubicin, paclitaxel or docetaxel\] and 14 cycles administered alone).

    Drug: Doxorubicin · Drug: Docetaxel · Drug: Paclitaxel · Drug: Trastuzumab

  • Experimental
    Trastuzumab (SID)

    Participants will receive trastuzumab 600 mg SC using SID q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy \[consisting of doxorubicin, paclitaxel or docetaxel\] and 14 cycles administered alone).

    Drug: Doxorubicin · Drug: Docetaxel · Drug: Paclitaxel · Drug: Trastuzumab

Interventions

  • Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.

  • Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.

  • Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.

  • Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

    Time frame: Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)

Secondary outcomes

  1. Actual Dose of Trastuzumab Administered

    Actual dose (mg) administered = (sum over all cycles of actual dose received \[mg\] divided by number of cycles). Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

    Time frame: Day 1 up last dose of trastuzumab (up to approximately 1 year)

  2. Duration of Treatment With Trastuzumab

    Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

    Time frame: Day 1 up last dose of trastuzumab (up to approximately 1 year)

  3. Percentage of Participants Who Received Concomitant Medications

    Time frame: Screening (Day -28 to -1) up to 2.5 years

  4. Percentage of Participants With Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography

    In the neoadjuvant setting, the activity of two sequential drug regimens, doxorubicin-containing chemotherapy followed by paclitaxel or docetaxel chemotherapy in combination with trastuzumab, was assessed as the percentage of participants with pCR in breast and nodes using mammography. pCR was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after preoperative treatment. Data for this outcome measure were analyzed and reported only for neoadjuvant groups within each treatment arm.

    Time frame: Day 1 up to 24 weeks

  5. Percentage of Participants With Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography

    A participant was considered as disease free if the participant was free from local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Percentage of participants with event at the cut off date were reported. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

    Time frame: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])

  6. Disease-Free Survival (DFS) Using Mammography

    DFS was defined as the time from the first treatment to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Kaplan-Meier estimates were used for analysis. Participants who were disease-free were censored at the data cut off date. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

    Time frame: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])

  7. Percentage of Participants Who Died

    Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

    Time frame: Day 1 up to death due to any cause (up to approximately 4.5 years)

  8. Overall Survival (OS)

    Overall survival was defined as the time from the first treatment to death from any cause. Kaplan-Meier estimates were used for analysis. Participants who did not die were censored on the date they were last known to be alive. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

    Time frame: Day 1 up to death due to any cause (up to approximately 4.5 years)

  9. Percentage of Participants by Response to Patient Satisfaction Questionnaire (PSQ)

    Participants were asked the following 5 questions: (1) "Following the first injection given by the physician/nurse and training on how to use the SID, I felt comfortable injecting the study drug by myself"; (2) "The SID was convenient and easy to use"; (3) "I am confident giving myself an injection in the thigh with the SID"; (4) "Taking all things into account, I find self-administration using the SID satisfactory"; (5) "If given the opportunity, I would choose to continue self-injecting the study drug using the SID at home". Response to each question was recorded as either of the following options: "Unknown", "Strongly Disagree", "Disagree", "Unsure", "Agree", "Strongly Agree". Percentage of participants who provided responses to above questions was reported. Data for this outcome measure were analyzed and reported only for Trastuzumab (SID) arm.

    Time frame: After at least 14 cycles (1 cycle = 21 days; maximum up to 1 year)

  10. Percentage of Health Care Professionals (HCPs) by Response to Health Care Professional Questionnaire (HCPQ)

    Percentage of HCPs providing responses to various questions related to overall ease of study drug administration was reported in different categories, where categories indicate all possible responses to such questions.

    Time frame: After at least 4 participants completed 5 cycles of adjuvant treatment (1 cycle = 21 days; maximum up to 1 year)

07

Results

Posted Jul 2, 2017

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab (Vial)Trastuzumab (SID)
Started121119
Treated115113
Treated: adjuvant9592
Treated: neoadjuvant2021
Completed100101
Not completed2118
Withdrew: Adverse event/intercurrent illness118
Withdrew: Recurrence of disease postsurgery13
Withdrew: Violation of entry criteria11
Withdrew: Refused treatment13
Withdrew: Withdrew consent62
Withdrew: Administrative/other11

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

Time frame:
Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Percentage of ParticipantsTrastuzumab (Vial): AdjuvantTrastuzumab (Vial): NeoadjuvantTrastuzumab (SID): AdjuvantTrastuzumab (SID): Neoadjuvant
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)98.9100.089.195.2
SecondaryActual Dose of Trastuzumab Administered

Actual dose (mg) administered = (sum over all cycles of actual dose received \[mg\] divided by number of cycles). Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

Time frame:
Day 1 up last dose of trastuzumab (up to approximately 1 year)
Reported as:
Mean · mg
Actual Dose of Trastuzumab Administered
mgTrastuzumab (Vial): AdjuvantTrastuzumab (Vial): NeoadjuvantTrastuzumab (SID): AdjuvantTrastuzumab (SID): Neoadjuvant
Actual Dose of Trastuzumab Administered599.7 ± 3.08600.00 ± 0.000593.3 ± 16.55595.9 ± 10.4
SecondaryDuration of Treatment With Trastuzumab

Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

Time frame:
Day 1 up last dose of trastuzumab (up to approximately 1 year)
Reported as:
Mean · days
Duration of Treatment With Trastuzumab
daysTrastuzumab (Vial): AdjuvantTrastuzumab (Vial): NeoadjuvantTrastuzumab (SID): AdjuvantTrastuzumab (SID): Neoadjuvant
Duration of Treatment With Trastuzumab346 ± 72.13352.2 ± 55.82340.1 ± 85.47351.9 ± 90.02
SecondaryPercentage of Participants Who Received Concomitant Medications
Time frame:
Screening (Day -28 to -1) up to 2.5 years
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Received Concomitant Medications
Percentage of ParticipantsTrastuzumab (Vial)Trastuzumab (SID)
Percentage of Participants Who Received Concomitant Medications100100
SecondaryPercentage of Participants With Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography

In the neoadjuvant setting, the activity of two sequential drug regimens, doxorubicin-containing chemotherapy followed by paclitaxel or docetaxel chemotherapy in combination with trastuzumab, was assessed as the percentage of participants with pCR in breast and nodes using mammography. pCR was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after preoperative treatment. Data for this outcome measure were analyzed and reported only for neoadjuvant groups within each treatment arm.

Time frame:
Day 1 up to 24 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography
Percentage of ParticipantsTrastuzumab (Vial): NeoadjuvantTrastuzumab (SID): Neoadjuvant
Percentage of Participants With Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography40.9 (31.0 to 51.0)15.8 (8.00 to 24.0)
SecondaryPercentage of Participants With Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography

A participant was considered as disease free if the participant was free from local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Percentage of participants with event at the cut off date were reported. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

Time frame:
Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])
Reported as:
Number · Percentage of Participants
Percentage of Participants With Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography
Percentage of ParticipantsTrastuzumab (Vial): AdjuvantTrastuzumab (Vial): NeoadjuvantTrastuzumab (SID): AdjuvantTrastuzumab (SID): Neoadjuvant
Percentage of Participants With Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography18.533.36.611.1
SecondaryDisease-Free Survival (DFS) Using Mammography

DFS was defined as the time from the first treatment to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Kaplan-Meier estimates were used for analysis. Participants who were disease-free were censored at the data cut off date. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

Time frame:
Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])
Reported as:
Median · Months
Disease-Free Survival (DFS) Using Mammography
MonthsTrastuzumab (Vial): AdjuvantTrastuzumab (Vial): NeoadjuvantTrastuzumab (SID): AdjuvantTrastuzumab (SID): Neoadjuvant
Disease-Free Survival (DFS) Using MammographyNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants Who Died

Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

Time frame:
Day 1 up to death due to any cause (up to approximately 4.5 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Died
Percentage of ParticipantsTrastuzumab (Vial): AdjuvantTrastuzumab (Vial): NeoadjuvantTrastuzumab (SID): AdjuvantTrastuzumab (SID): Neoadjuvant
Percentage of Participants Who Died5.24.50.05.26
SecondaryOverall Survival (OS)

Overall survival was defined as the time from the first treatment to death from any cause. Kaplan-Meier estimates were used for analysis. Participants who did not die were censored on the date they were last known to be alive. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.

Time frame:
Day 1 up to death due to any cause (up to approximately 4.5 years)
Reported as:
Median · Months
Overall Survival (OS)
MonthsTrastuzumab (Vial): AdjuvantTrastuzumab (Vial): NeoadjuvantTrastuzumab (SID): AdjuvantTrastuzumab (SID): Neoadjuvant
Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants by Response to Patient Satisfaction Questionnaire (PSQ)

Participants were asked the following 5 questions: (1) "Following the first injection given by the physician/nurse and training on how to use the SID, I felt comfortable injecting the study drug by myself"; (2) "The SID was convenient and easy to use"; (3) "I am confident giving myself an injection in the thigh with the SID"; (4) "Taking all things into account, I find self-administration using the SID satisfactory"; (5) "If given the opportunity, I would choose to continue self-injecting the study drug using the SID at home". Response to each question was recorded as either of the following options: "Unknown", "Strongly Disagree", "Disagree", "Unsure", "Agree", "Strongly Agree". Percentage of participants who provided responses to above questions was reported. Data for this outcome measure were analyzed and reported only for Trastuzumab (SID) arm.

Time frame:
After at least 14 cycles (1 cycle = 21 days; maximum up to 1 year)
Reported as:
Number · Percentage of Participants
Percentage of Participants by Response to Patient Satisfaction Questionnaire (PSQ)
Percentage of ParticipantsTrastuzumab (SID)
Comfortable: Unknown0.0
Comfortable: Strongly Disagree0.0
Comfortable: Disagree0.0
Comfortable: Unsure6.7
Comfortable: Agree40
Comfortable: Strongly Agree53.3
Convenient: Unknown0.0
Convenient: Strongly Disagree0.0
Convenient: Disagree0.0
Convenient: Unsure6.7
Convenient: Agree33.3
Convenient: Strongly Agree60
Confident: Unknown0.0
Confident: Strongly Disagree0.0
Confident: Disagree0.0
Confident: Unsure6.7
Confident: Agree40.0
Confident: Strongly Agree53.3
Satisfactory: Unknown0.0
Satisfactory: Strongly Disagree0.0
Satisfactory: Disagree0.0
Satisfactory: Unsure6.7
Satisfactory: Agree33.3
Satisfactory: Strongly Agree60
Would continue: Unknown0.0
Would continue: Strongly Disagree0.0
Would continue: Disagree13.3
Would continue: Unsure6.7
Would continue: Agree20
Would continue: Strongly Agree60
SecondaryPercentage of Health Care Professionals (HCPs) by Response to Health Care Professional Questionnaire (HCPQ)

Percentage of HCPs providing responses to various questions related to overall ease of study drug administration was reported in different categories, where categories indicate all possible responses to such questions.

Time frame:
After at least 4 participants completed 5 cycles of adjuvant treatment (1 cycle = 21 days; maximum up to 1 year)
Reported as:
Number · Percentage of HCPs
Percentage of Health Care Professionals (HCPs) by Response to Health Care Professional Questionnaire (HCPQ)
Percentage of HCPsHCPs: Trastuzumab (Vial)HCPs: Trastuzumab (SID)
Specialization: Oncologist17.316.0
Specialization: Specialist nurse69.276.0
Specialization: Other11.58.0
Specialization: Missing1.90.0
Personally administered/supervised: Always40.448.0
Personally administered/supervised: Sometimes51.948.0
Personally administered/supervised: Never7.74.0
If 'Never', who administered: Specialist nurse7.74.0
Syringe prepared at: Pharmacy55.8NA
Syringe prepared at: Oncology ward40.4NA
Syringe prepared at: Missing3.8NA
Time to fill syringe: less than (<) 5 minutes67.3NA
Time to fill syringe: 6-10 minutes13.5NA
Time to fill syringe: 11-15 minutes5.8NA
Time to fill syringe: Unknown13.5NA
Total time for vial administration: <3 minutes1.9NA
Total time for vial administration: <5 minutes59.6NA
Total time for vial administration: 6-15 minutes38.5NA
Time to prepare SID: <5 minutesNA72.0
Time to prepare SID: 6-10 minutesNA14.0
Time to prepare SID: 11-15 minutesNA4.0
Time to prepare SID: 16-20 minutesNA2.0
Time to prepare SID: >20 minutesNA8.0
Total time for SID administration: <3 minutesNA26.0
Total time for SID administration: <5 minutesNA30.0
Total time for SID administration: 6-15 minutesNA44.0
Injection site: Irritation: A lot1.94.0
Injection site: Irritation: A few46.236.0
Injection site: Irritation: None51.960.0
Injection site: Bruising: A few7.710.0
Injection site: Bruising: None92.390.0
Injection site: Infection: None100.0100.0
Fever,shivering,flu-like,rash,swelling:A few15.414.0
Fever,shivering,flu-like,rash,swelling:None84.686.0
Time at hospital for administration: <2 hours44.244.0
Time at hospital for administration: >2, <3 hours23.134.0
Time at hospital for administration: >3, <4 hours23.112.0
Time at hospital for administration: >4 hours7.710.0
Time at hospital for administration: Missing1.90.0
Anxiety to participants: None82.790.0
Anxiety to participants: A fair amount17.310.0
Ease of vial administration: None5.8NA
Ease of vial administration: A fair amount38.5NA
Ease of vial administration: A lot55.8NA
Subcutaneous route may simplify management: Yes94.2100.0
Subcutaneous route may simplify management: No5.80.0
Would recommend SID to intravenous route: Yes96.296.0
Would recommend SID to intravenous route: No3.84.0
Would recommend subcutaneous route to medics: Yes100.090.0
Would recommend subcutaneous route to medics: No0.08.0
Would recommend subcutaneous to medics:Missing0.02.0
Convenience of using SID by participants: Yes94.296.0
Convenience of using SID by participants: No0.04.0
Convenience of using SID by participants: Missing5.80.0

Adverse events

Collected over Day 1 up to 28 days after last dose of trastuzumab. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab (Vial): Adjuvant5/95 (5.3%)5/95 (5.3%)92/95 (96.8%)
Trastuzumab (Vial): Neoadjuvant1/20 (5%)3/20 (15%)20/20 (100%)
Trastuzumab (SID) Adjuvant0/92 (0%)7/92 (7.6%)79/92 (85.9%)
Trastuzumab (SID) Neoadjuvant1/21 (4.8%)2/21 (9.5%)18/21 (85.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventTrastuzumab (Vial): AdjuvantTrastuzumab (Vial): NeoadjuvantTrastuzumab (SID) AdjuvantTrastuzumab (SID) Neoadjuvant
Atrial fibrillationCardiac disorders0/951/200/920/21
PleuropericarditisCardiac disorders0/951/200/920/21
GastroenteritisInfections and infestations0/951/200/920/21
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/951/200/920/21
VomitingGastrointestinal disorders0/950/200/921/21
NeutropeniaBlood and lymphatic system disorders0/950/200/921/21
Febrile neutropeniaBlood and lymphatic system disorders0/950/201/920/21
PryexiaGeneral disorders0/950/201/920/21
Anaphylactic shockImmune system disorders1/950/201/920/21
Bladder transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/950/201/920/21
Most frequent other events
Showing 10 of 82
Most frequent other events
EventTrastuzumab (Vial): AdjuvantTrastuzumab (Vial): NeoadjuvantTrastuzumab (SID) AdjuvantTrastuzumab (SID) Neoadjuvant
ParaesthesiaNervous system disorders49/953/2025/923/21
AstheniaGeneral disorders32/953/2020/927/21
ArthralgiaMusculoskeletal and connective tissue disorders29/954/2028/925/21
DiarrhoeaGastrointestinal disorders25/953/2015/926/21
Hot flushVascular disorders7/955/207/922/21
HypertensionVascular disorders7/955/208/921/21
ErythemaSkin and subcutaneous tissue disorders23/952/2014/922/21
NeutropeniaBlood and lymphatic system disorders20/954/204/920/21
PyrexiaGeneral disorders18/954/2013/924/21
AnaemiaBlood and lymphatic system disorders15/952/207/924/21

Baseline characteristics

Intent-to-treat (ITT) population included all enrolled participants.

Age, Continuous
Age, Continuous(years)Trastuzumab (Vial)Trastuzumab (SID)Total
Mean55.1 ± 10.5153.2 ± 10.3754.2 ± 10.46
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab (Vial)Trastuzumab (SID)Total
Female120119239
Male101
08

Study locations

54 sites
  • Asl 4 - Osp. San Salvatore; Oncologia Medica
    L'aquila, Abruzzo 67010, Italy
  • Ospedale San Carlo; Day Hospital Oncologia Medica
    Potenza, Basilicata 85100, Italy
  • Campus Universitario S.Venuta; Centro Oncologico T.Campanella
    Catanzaro, Calabria 88100, Italy
  • Az. Osp. ; Divisione Oncologia Medica
    Reggio Calabria, Calabria 89100, Italy
  • Azienda Ospedaliera S.G. Moscati; Division of Medical Oncology
    Avellino, Campania 83100, Italy
  • Presidio Ospedaliero S. Giovanni Di Dio; U.O. Di Oncologia
    Frattamaggiore, Campania 80027, Italy
  • Seconda Università di Napoli;Day Hospital Clinica Oncologia Medica
    Napoli, Campania 80131, Italy
  • Ospedale Bellaria; U.O. Oncologia Medica
    Bologna, Emilia-Romagna 40133, Italy
  • Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
    Bologna, Emilia-Romagna 40138, Italy
  • Ospedale Ramazzini ; Day Hospital Oncologico
    Carpi, Emilia-Romagna 41012, Italy
  • Ospedale Civile; Day Hospital Oncologico
    Guastalla, Emilia-Romagna 42016, Italy
  • Arcispedale Santa Maria Nuova; Oncologia
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
    Aviano, Friuli-Venezia Giulia 33081, Italy
  • Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia
    Udine, Friuli-Venezia Giulia 33100, Italy
  • Policlinico A. Gemelli-Complesso Integrato Columbus-Radioterapia
    Roma, Lazio 00168, Italy
  • Uni Cattolica Policlinico Gemelli; Oncologia Medica Ist. Medicina Interna
    Roma, Lazio 00168, Italy
  • Ospedale S.G.Calibita Fatebenefratelli; Unità Operativa Oncologia
    Roma, Lazio 00186, Italy
  • Villa San Pietro Fatebenefatelli; Divisione Oncologia
    Roma, Lazio 00189, Italy
  • Az. Osp. Uni Ria San Martino; Cliniche Uni Rie Convenzionate U.O. Oncologia Medical
    Genova, Liguria 16132, Italy
  • IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
    Genova, Liguria 16132, Italy
  • Ospedale Civile S. Andrea; Day Hospital Oncologia
    La Spezia, Liguria 19125, Italy
  • Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina
    Brescia, Lombardia 25123, Italy
  • Casa Di Cura Poliambulanza; Unita Operativa Di Oncologia Medica
    Brescia, Lombardia 25124, Italy
  • Ospedale Valduce;U.O.S. Oncologia Ed Ematologia
    Como, Lombardia 22100, Italy
  • ASST DI LECCO; Oncologia Medica
    Lecco, Lombardia 23900, Italy
  • Az. Osp. Carlo Poma; Divisione Di Oncologia Medica
    Mantova, Lombardia 46100, Italy
  • Irccs Ospedale San Raffaele;Oncologia Medica
    Milano, Lombardia 20132, Italy
  • Istituto Europeo Di Oncologia
    Milano, Lombardia 20141, Italy
  • Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica
    Pavia, Lombardia 27100, Italy
  • Az. Osp. Di Busto P.O. Di Saronno; U.O. Di Oncologia Medica
    Saronno, Lombardia 21047, Italy
  • ASST DI BERGAMO OVEST; Unità Operativa di Oncologia Medica
    Treviglio, Lombardia 24047, Italy
  • Ospedale Di Circolo E Fondazione Macchi; Oncologia Medica
    Varese, Lombardia 21100, Italy
  • A.O.U. Ospedali Riuniti Umberto I-G.M.Lancisi-G.Salesi Ancona;S.O.D. MED.Interna-Clinica Oncologica
    Ancona, Marche 60121, Italy
  • Ospedale Di Macerata; Oncologia
    Macerata, Marche 62100, Italy
  • Ospedale San Salvatore Muraglia;Divisone Oncologia
    Pesaro, Marche 61122, Italy
  • Azienda Sanitaria Locale Di Asti-P.O. Cardinal Massaia;Oncologia
    Asti, Piemonte 14100, Italy
  • Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico
    Candiolo, Piemonte 10060, Italy
  • Azienda Sanitaria Ospedaliera s. Croce e Carle; Oncologia Medica
    Cuneo, Piemonte 12100, Italy
  • Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica
    Ponderano (BI), Piemonte 13875, Italy
  • Ospedale Mauriziano Umberto I; Divisione Onco-Ematologia
    Torino, Piemonte 10128, Italy
  • Centro Catanese Di Oncologia; Oncologia Medica
    Catania, Sicilia 95126, Italy
  • Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia
    Arezzo, Toscana 52100, Italy
  • Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1
    Firenze, Toscana 50139, Italy
  • Ospedale della Misericordia; Hospice Terapia del Dolore
    Grosseto, Toscana 58100, Italy
  • Ospedale Nuovo Della Versilia; Divisione Di Oncologia Medica
    Lido Di Camaiore, Toscana 55043, Italy
  • Ospedale Civile; Unita Operativa Di Oncologia Medica
    Livorno, Toscana 57100, Italy
  • Azienda Usl 7; Dept. Oncologico
    Poggibonsi, Toscana 53036, Italy
  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
    Sant'Andrea Delle Fratte (PG), Umbria 06132, Italy
  • Presidio Ospedaliero - Usl 13; Servizio Di Oncologia
    Castelfranco Veneto, Veneto 31033, Italy
  • AZ. Usll12 Veneziana-Ospedale Dell'angelo;Oncologia Medica
    Mestre, Veneto 30174, Italy
  • Ospedale Calvi di Noale; U.O. Complessa di Oncologia ed Ematologia Oncologica
    Mirano, Veneto 30035, Italy
  • Ospedale Sacro Cuore Don Calabria; U.O. Di Oncologia
    Negrar, Veneto 37024, Italy
  • Ospedale Cà Foncello - Divisione di Oncologia Medica
    Treviso, Veneto 31100, Italy
  • Ospedale Di Vicenza; Nefrologia, Oncologia Medica
    Vicenza, Veneto 36100, Italy
09

References and documents

Publications

  • Zambetti M, Montemurro F, Morandi P, Zamagni C, Brandes AA, Bisagni G, Cagossi K, Bengala C, Gori S, Iannacone C, Stell A, Gianni L. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. Eur J Cancer. 2018 Dec;105:61-70. doi: 10.1016/j.ejca.2018.09.034. Epub 2018 Nov 3. PubMed 30396014 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Apr 2016, 28 months.

Results were first posted in Jul 2017, 1 year 2 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 28 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2013
First posted
Sep 12, 2013
StartActual
Nov 15, 2013
Primary completionActual
Apr 5, 2016
CompletionActual
Mar 27, 2018
Results first posted
Jul 2, 2017
Last update
Nov 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01940497
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 12, 2013
Start date
Nov 15, 2013
Primary completion
Apr 5, 2016
Completion
Mar 27, 2018
Results posted
Jul 2, 2017
Last update
Nov 3, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion